Import from '@/components/mdx'

CJC-1295 Complete Drug-Drug Interaction Profile: What Every Woman Needs to Know

What CJC-1295 Is and How It Works

CJC-1295 is a synthetic, 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells, triggering pulsatile release of endogenous growth hormone (GH). That GH pulse then drives hepatic and peripheral production of insulin-like growth factor-1 (IGF-1), which mediates most of the anabolic and lipolytic effects women seek from this compound.

DAC vs. No-DAC: Why It Matters Clinically

The critical pharmacokinetic difference between the two forms comes down to the Drug Affinity Complex (DAC) modification. The DAC variant covalently attaches to albumin, extending the peptide's plasma half-life from approximately 30 minutes to 6-8 days. In the landmark Teichman et al. Study published in the Journal of Clinical Endocrinology and Metabolism, a single 30 mcg/kg or 60 mcg/kg dose of CJC-1295 DAC produced sustained, dose-dependent GH and IGF-1 elevation for up to 8 days, with mean IGF-1 increases of 35-89% above baseline depending on dose.

That prolonged elevation is exactly what drives the drug's interaction risk profile. A compound that keeps GH and IGF-1 high for a week creates sustained pressure on glucose metabolism, thyroid axis feedback, and sex-hormone-binding globulin (SHBG) levels. This is not a short pharmacodynamic window you can easily manage by spacing doses from other medications.

Why the Pituitary Axis Makes Interactions Harder to Predict

GH operates at a physiological crossroads. It antagonizes insulin signaling at the postreceptor level, it suppresses TSH sensitivity in some tissues, it alters cortisol clearance, and it changes the ratio of free to bound sex hormones by suppressing SHBG. Every drug that touches those same axes becomes a potential interaction partner.

The Complete Drug-Drug Interaction Profile

The interaction categories below are organized by mechanism, not severity, because severity depends heavily on your life stage, your baseline hormone environment, and which other drugs you are taking. A perimenopausal woman on levothyroxine faces a meaningfully different risk calculus than a 28-year-old with no thyroid condition.

Insulin and All Antidiabetic Agents

This is the most clinically significant interaction class. GH is a counter-regulatory hormone. It directly impairs insulin receptor substrate (IRS-1) signaling by increasing serine phosphorylation, reducing glucose uptake in skeletal muscle, and increasing hepatic glucose output. Women using CJC-1295 alongside insulin, sulfonylureas, meglitinides, or GLP-1 receptor agonists must expect this blunting effect.

The PCOS Caveat

Women with polycystic ovary syndrome already carry baseline insulin resistance driven by hyperandrogenism and often by excess adipose tissue. Adding a GH secretagogue that further impairs insulin signaling is a meaningful concern. The ESHRE/ASRM PCOS guidelines do not address GH secretagogues directly, but the physiology is clear: GH excess worsens hyperinsulinemia, and hyperinsulinemia worsens androgen production. Women with PCOS using metformin should monitor fasting glucose and fasting insulin more frequently, as the efficacy of metformin may appear blunted during CJC-1295 use.

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)

Combining CJC-1295 with GLP-1 receptor agonists is increasingly common in compounding clinic practice. GLP-1 agents lower fasting glucose; CJC-1295 raises it. The net glycemic effect is unpredictable and patient-specific. There are no published head-to-head trial data on this combination in women. This is an extrapolation from known pharmacodynamics, not a directly studied interaction. Women on semaglutide for weight management who add CJC-1295 should check fasting glucose monthly for the first 90 days.

Thyroid Hormones and Antithyroid Drugs

Elevated IGF-1 alters thyroid hormone metabolism in at least two ways. First, GH increases type-1 deiodinase activity, increasing conversion of T4 to the active T3. Second, GH may lower thyroxine-binding globulin (TBG), increasing the free T4 fraction transiently. Both effects can make a previously stable levothyroxine dose feel too strong: symptoms of over-replacement such as palpitations, insomnia, and anxiety can appear even when the patient has not changed her thyroid dose.

Postpartum thyroiditis and Hashimoto thyroiditis, both female-predominant conditions, add a layer of volatility. A woman in the hypothyroid phase of postpartum thyroiditis whose levothyroxine dose was just stabilized may find that starting CJC-1295 throws her TSH off within 4-6 weeks. Check TSH and free T4 approximately six weeks after initiating or up-titrating CJC-1295 in any woman on thyroid replacement.

Women taking propylthiouracil (PTU) or methimazole for Graves disease face the opposite problem: GH-driven increases in T4-to-T3 conversion may worsen hyperthyroid symptoms if antithyroid dosing is not adjusted.

Glucocorticoids

Glucocorticoids and GH sit on opposing sides of the somatotropic axis. Chronic glucocorticoid use suppresses GHRH-driven GH secretion at the pituitary level and reduces hepatic IGF-1 production. Women taking prednisone, dexamethasone, or inhaled fluticasone at high doses for autoimmune conditions (lupus, rheumatoid arthritis, severe asthma) may see a blunted CJC-1295 response, not an amplified risk, but the counter-pressure on glucose control still adds up. Both glucocorticoids and GH elevation raise fasting glucose; together they can push a woman with pre-diabetes into overt hyperglycemia.

Adrenal insufficiency managed with hydrocortisone replacement requires particular attention. GH accelerates cortisol clearance by inducing 11-beta-HSD1 activity, potentially making a fixed hydrocortisone replacement dose feel insufficient. Women on cortisol replacement who start CJC-1295 should discuss symptom monitoring for adrenal insufficiency with their prescribing clinician.

Sex Hormones: Estrogen, Progesterone, and Androgens

This is where women's physiology diverges most clearly from the male-default literature.

Estrogen and SHBG

Oral estrogen raises SHBG by its first-pass hepatic effect. GH and IGF-1 suppress SHBG. These effects are antagonistic. A postmenopausal woman taking oral estradiol for menopause symptom management and adding CJC-1295 may find that the GH-driven SHBG suppression partially counteracts the estrogen-driven SHBG rise, leaving more free testosterone and more free estradiol in circulation. The clinical consequence depends on context. In a woman with hormone-sensitive breast tissue, this shift in free hormone fractions deserves monitoring. In a woman with low libido partly driven by high SHBG, it might actually help.

Transdermal estradiol bypasses hepatic first-pass and has a smaller effect on SHBG, so this interaction is less pronounced with patches, gels, or sprays than with oral estradiol.

Testosterone Therapy in Women

Women prescribed low-dose testosterone (typically 0.5-2 mg/day) for HSDD or energy, a practice supported by The Menopause Society position statement, add another variable when CJC-1295 is co-administered. GH and testosterone are broadly anabolic and co-stimulating in muscle tissue, but the combination also amplifies IGF-1 signaling. Elevated IGF-1 with androgen exposure has been associated with acne vulgaris and, in susceptible women, androgenic alopecia. Free testosterone levels may rise further if GH suppresses SHBG significantly.

Oral Contraceptives

Combined oral contraceptives (COCs) containing ethinyl estradiol raise SHBG substantially. GH suppresses SHBG. Women on COCs who start CJC-1295 may experience a net shift toward more free androgens, which could worsen hormonal acne or increase androgenic symptoms in susceptible women. This is mechanistically predicted but not yet studied prospectively in women.

Insulin-like Growth Factor Pathway Drugs: IGF-1 Concerns With Cancer History

IGF-1 is a mitogenic signal. Epidemiological data consistently link high circulating IGF-1 to breast cancer risk, and IGF-1 receptors are overexpressed in many breast cancers. Women with a personal history of hormone-sensitive or IGF-1-receptor-positive breast cancer should treat CJC-1295 as contraindicated until direct evidence of safety exists. This is not currently studied. Tamoxifen and aromatase inhibitors do not directly interact with the GHRH receptor, but the oncological logic of elevating IGF-1 in a woman on adjuvant breast cancer therapy is deeply concerning.

Opioids and CNS Depressants

Opioids inhibit GHRH secretion and reduce pulsatile GH release at the hypothalamic level. Women on long-term opioid therapy for chronic pain already have suppressed somatotropic axis activity. CJC-1295 partially counteracts that suppression, but the net GH response is lower than in opioid-naive patients. This is relevant for dose expectations, not for acute safety. Benzodiazepines and sedative-hypnotics do not appear to meaningfully interact with the GHRH receptor based on current mechanistic data.

Recombinant Human GH (rhGH) and Other GH Secretagogues

Co-administering CJC-1295 with exogenous rhGH (somatropin) or with other GH secretagogues such as ipamorelin, MK-677 (ibutamoren), or sermorelin creates a stacked GH signal. GH excess produces acromegalic physiology at high enough concentrations: carpal tunnel syndrome, edema, joint pain, glucose intolerance, and in theory, increased IGF-1-driven proliferative signaling. Ipamorelin is the most commonly co-prescribed partner. The CJC-1295 plus ipamorelin combination is widespread in compounding practice, but there are no controlled safety trials in women or men. This represents a significant evidence gap.

Life-Stage-Specific Considerations

Reproductive Years (Ages 18-40)

GH pulsatility naturally peaks in the late teens and early 20s and declines progressively. Women in their reproductive years considering CJC-1295 are often seeking body composition changes, faster recovery, or treatment of an underlying GH deficiency. The interaction profile above applies, but this group faces one additional variable: menstrual cycle phase. Estradiol rises in the follicular phase and may transiently augment GH secretion; progesterone in the luteal phase blunts the GH pulse. Women may notice that CJC-1295 feels different at different points in their cycle. This is expected physiology, not a drug quality issue.

Trying to Conceive

Do not use CJC-1295 while actively trying to conceive. The evidence base for GH secretagogue use in fertility is limited to a small number of trials using exogenous rhGH as an adjuvant in poor ovarian responders, and those trials used controlled clinical doses under direct supervision, not open-ended compounded CJC-1295. ASRM practice guidelines on adjuvant GH in poor responders do not endorse unsupervised GH secretagogue use during fertility treatment.

Perimenopause

This is the life stage with the most clinically relevant pharmacodynamic amplification. Estradiol decline in perimenopause coincides with an accelerated drop in pulsatile GH secretion. Women aged 45-55 therefore show a larger relative IGF-1 response to CJC-1295 than younger women, because they are starting from a lower baseline. The Teichman et al. Trial did not stratify by menopausal status, so the degree of IGF-1 amplification in perimenopausal women is extrapolated, not directly measured. This is an important data gap. Perimenopausal women on menopausal hormone therapy (MHT) face the estrogen-SHBG-GH interaction described above and should monitor free hormone levels if combining CJC-1295 with oral estradiol.

Postmenopause

Postmenopausal women have the lowest baseline GH and IGF-1 of any adult female life stage. IGF-1 response to CJC-1295 may be proportionally larger. Bone turnover markers should be monitored, because GH elevation accelerates bone remodeling; this is generally favorable for bone density but can temporarily increase bone resorption markers before accretion catches up. Women on bisphosphonates or denosumab will not have a pharmacokinetic interaction with CJC-1295, but the combination creates a dual bone-targeted signal whose net effect has not been studied in postmenopausal women.

Pregnancy, Lactation, and Contraception

CJC-1295 is contraindicated in pregnancy. There is no human pregnancy safety data. The drug has no FDA approval and no pregnancy category designation, but based on the physiological role of the IGF-1 axis in fetal development and the absence of any safety signal from controlled trials, use during pregnancy cannot be justified. IGF-1 is a major driver of fetal growth, and exogenous manipulation of the GH/IGF-1 axis during organogenesis or fetal growth phases carries theoretical risk of abnormal growth programming.

Lactation: GH and IGF-1 are detectable in human breast milk physiologically, but whether peptide fragments from CJC-1295 or its albumin-bound DAC metabolites transfer into milk is unknown. Given the long half-life of the DAC variant (6-8 days), clearance cannot be achieved quickly. Avoid CJC-1295 entirely during breastfeeding.

Contraception requirement: Women of reproductive age must use reliable contraception during CJC-1295 use. Because the DAC variant remains pharmacologically active for up to 8 days after injection, a woman who discovers an unintended pregnancy should be counseled that fetal exposure in the weeks immediately before recognition of pregnancy is possible. Discuss contraception method explicitly before prescribing.

The FDA has not approved CJC-1295 for any indication, and its availability through 503A compounding pharmacies means there is no manufacturer label to guide pregnancy or lactation decisions. Clinicians must rely on first-principles endocrinology.

Who This Drug May Be Appropriate For, and Who It Is Not

Women who may be reasonable candidates for supervised CJC-1295 use include those with documented adult GH deficiency confirmed by stimulation testing, those pursuing body composition optimization under direct endocrine supervision, and postmenopausal women with low IGF-1 who have been counseled on the lack of long-term safety data.

Women for whom CJC-1295 should be avoided include:

• Anyone currently pregnant or breastfeeding
• Women with a personal history of breast cancer, ovarian cancer, or any malignancy where IGF-1 may drive proliferation
• Women with active acromegaly or pituitary adenoma
• Women with uncontrolled type 2 diabetes or pre-diabetes without close glucose monitoring in place
• Women with PCOS who are not simultaneously managing insulin resistance with a structured approach
• Women with active Graves disease or uncontrolled thyroid dysfunction
• Women taking tamoxifen or aromatase inhibitors for breast cancer treatment or prevention

Monitoring Parameters for Women Using CJC-1295

A practical monitoring schedule should include serum IGF-1 at baseline and at 8 weeks after initiating the DAC variant (to capture the steady-state plateau), fasting glucose and fasting insulin at baseline and at 12 weeks, TSH and free T4 at 6 weeks in any woman on thyroid replacement, SHBG and free testosterone at baseline and at 12 weeks if the woman is also using testosterone therapy or a combined oral contraceptive, and bone turnover markers at 6 months in postmenopausal women.

The target IGF-1 range in clinical GH optimization practice is generally the upper quartile of the age-matched female reference range, not supraphysiologic levels. Levels above 400 ng/mL in women aged 30-60 should prompt dose reduction or temporary discontinuation.

Evidence Gaps Women Should Know About

Women have been systematically under-represented in GH research. The Teichman et al. Trial enrolled healthy adults but did not publish sex-stratified subgroup analyses for most endpoints. The effect of female reproductive hormone fluctuation on CJC-1295 pharmacodynamics has not been prospectively studied. Interaction data with hormonal contraceptives, MHT, and PCOS-specific medications are entirely extrapolated from mechanism, not from trial data. Any clinician who tells you the drug is "well-studied in women" is overstating the evidence base. The honest position is that we know the mechanism, we have limited but informative human pharmacokinetic data, and the interaction profile must be managed conservatively until more sex-disaggregated data exist.

If your IGF-1 rises above the upper limit of the age-specific female reference range within 8 weeks of starting CJC-1295 DAC at a dose of 30 mcg/kg, reduce the dose before the next injection rather than waiting for the 12-week review.